Regulation
Glucotrack seeks FDA approval for clinical study of CBGM technology
Glucotrack has submitted an Investigational Device Exemption (IDE) application to the FDA to initiate a clinical study of its continuous blood glucose monitoring (CBGM) technology in the United States. The filing marks a regulatory milestone toward potential market clearance for the glucose monitoring system.
The source
This brief is a MedIndexer summary of reporting by Medical Device Network. To read the full story, head to the source.
Read the full story at Medical Device Network